Nutra Pharma Begins Drug Registration Process In Central America For Its Nyloxin Pain Reliever

June 24, 2010

Nutra Pharma Has Begun the Drug Registration Process in Panama for Its Nyloxin Pain Reliever

Coral Springs, FL (Marketwire) - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that it has begun the drug registration process in Panama for its Nyloxin pain reliever.

"As an important international business center, Panama offers us an opportunity to introduce our Nyloxin pain reliever in Central America," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "We plan to move forward with this drug registration process in conjunction with finalizing our relationship with a prospective local distribution partner that has the resources and capabilities to successfully market and distribute Nyloxin throughout the country," he concluded.

Continue reading

*

Share |

*

****************************************************************

"Providing You with 'MS Views and News', is what we do"

Keep Informed and up-to-date with information concerning

 Multiple Sclerosis when registered at

the MS Views and News website.

(This will take 20-25 seconds and will empower you

 with informaton and learning)

Thank you for allowing me to help to keep you informed

****************************************************************